Get started
Author

Alicia Clawson

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
2018 · Antoine Italiano, Jean-Charles Soria, et al. · The Lancet Oncology · 662
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
2018 · Eytan M. Stein, Guillermo Garcia-Manero, et al. · Blood · 474
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
2009 · William J. Gradishar, Dimitry Krasnojon, et al. · Journal of Clinical Oncology · 344
Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes
2007 · Joanne L. Blum, Michael A. Savin, et al. · Clinical Breast Cancer · 172
A phase 2 clinical trial of nab‐paclitaxel in previously treated and chemotherapy‐naive patients with metastatic melanoma
2009 · Evan M. Hersh, Steven J. O'Day, et al. · Cancer · 122
PDF
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
2012 · William J. Gradishar, Dimitry Krasnojon, et al. · Clinical Breast Cancer · 120
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
2015 · E.M. Hersh, M. Del Vecchio, et al. · Annals of Oncology · 102
PDF
Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
2010 · Alison K. Conlin, Andrew D. Seidman, et al. · Clinical Breast Cancer · 92
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B‐cell Non‐hodgkin Lymphomas
2017 · F. Morschhauser, G. Salles, et al. · Hematological Oncology · 65
PDF
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
2018 · Marjorie Glass Zauderer, Peter Szlosarek, et al. · Journal of Clinical Oncology · 53
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).
2017 · Patrick Schoffski, Mark Agulnik, et al. · Journal of Clinical Oncology · 53
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
2025 · Rohit Loomba, Kris V Kowdley, et al. · The Lancet. Gastroenterology & hepatology · 52
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET -altered tumors including RET -fusion+ NSCLC and RET -mutant MTC: Phase 1 study results.
2021 · Patrick Schoffski, Byoung Chul Cho, et al. · Journal of Clinical Oncology · 45
Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
2013 · Andrew D. Seidman, Alison K. Conlin, et al. · Clinical Breast Cancer · 32
Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
2007 · W. Gradishar, D. Krasnojon, et al. · Journal of Clinical Oncology · 29
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma.
2016 · Mark Agulnik, Nizar M. Tannir, et al. · Journal of Clinical Oncology · 26
Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).
2017 · Mrinal M. Gounder, Silvia Stacchiotti, et al. · Journal of Clinical Oncology · 25
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
2010 · Nicholas Robert, Lea Krekow, et al. · Breast Cancer Research and Treatment · 25
Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
2009 · A. K. Conlin, C. A. Hudis, et al. · Journal of Clinical Oncology · 24
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
2018 · R.L. Jones, J.-Y. Blay, et al. · Annals of Oncology · 20
Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
2011 · John Pippen, Devchand Paul, et al. · Breast Cancer Research and Treatment · 19
Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
2018 · Susan Chi, Maryam Fouladi, et al. · Molecular Cancer Therapeutics · 17
Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
2018 · John Pagel, Franck Morschhauser, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.
2011 · W. J. Gradishar, D. Krasnojon, et al. · Journal of Clinical Oncology · 9
A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
2016 · Susan N. Chi, Geoffrey Brian McCowage, et al. · Journal of Clinical Oncology · 8
Works count: 42
Citation count: 2,660
H-index: 20
I10-index: 23
Year
Topic
Type